康泰生物 (300601)
Shenzhen Kangtai Biological Products Co.,Ltd.
K-Line Chart
No K-line data available
Company NameShenzhen Kangtai Biological Products Co., Ltd.
Listing Date2017-02-07
Issue Price3.29RMB
Registered Capital111692.788710k RMB
Legal RepresentativeDu Weimin
Registered Address101, Kangtai Group Building, No. 222 Kefa Road, Kejiyuan Community, Yuehai Street, Nanshan District, Shenzhen City, Guangdong Province
IndustryBiological Products
Main BusinessResearch, development, production, and sales of human vaccines
Company ProfileShenzhen Kangtai Biological Products Co., Ltd. is a listed company integrated with R&D, production, and sales of biological products, with stock code 300601. Headquartered in Shenzhen, the company has R&D centers and industrial bases in both Shenzhen and Beijing, and is one of China's major hepatitis B vaccine manufacturers. Its main business is the research, development, production, and sales of human vaccines. Its product portfolio includes Category I and Category II vaccines. Current major products include Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, Measles and Rubella Combined Attenuated Live Vaccine, Acellular Pertussis, Diphtheria, Tetanus and Haemophilus influenzae type b Combined Vaccine (DTaP-Hib), 23-valent Pneumococcal Polysaccharide Vaccine, among others. Since its establishment in 1992, Kangtai Biological has undertaken multiple national, provincial, and municipal key scientific research projects and technology development tasks. It has established core competitiveness in the R&D and industrialization of new technologies such as multivalent combination vaccines and genetic engineering vaccines. The company possesses eight R&D platforms, including an Academician Expert Workstation, and its products reach over 30 provinces, municipalities, and autonomous regions. Among them, the independently developed Acellular Pertussis, Diphtheria, Tetanus and Haemophilus influenzae type b Combined Vaccine (DTaP-Hib) is an innovative domestic exclusive 'quadrivalent vaccine'. The 60μg hepatitis B vaccine specifically designed for non-responder populations holds the title of 'National Key New Product'.
Stock Details
1. Key Indicators
- Total Shares(W): 111692.92
- Circulating A-Shares(W): 90039.62
- Earnings Per Share(RMB): 0.0400
- Net Assets Per Share(RMB): 8.1469
- Operating Revenue(W RMB): 206344.30
- Total Profit(W RMB): 20.23
- Net Profit Attributable to Parent(W RMB): 4915.77
- Net Profit Growth Rate(%): -86.00
- Weighted Return on Equity(%): 0.5100
- Operating Cash Flow Per Share(RMB): 0.3250
- Undistributed Profit Per Share(RMB): 1.9017
- Capital Reserve Per Share(RMB): 4.9347
2. Main Business
The main business covers:
- Research, development, production and sales of human vaccines
3. Company Basic Information
- Company Name: Shenzhen Kangtai Biological Products Co., Ltd.
- Listing Date: 2017-02-07
- Industry: Pharmaceutical Manufacturing
- Address: Kangtai Group Building, No. 222 Kefa Road, Science Park Community, Yuehai Street, Nanshan District, Shenzhen City, Guangdong Province
- Website: www.biokangtai.com
- Company Profile: The company was established on December 11, 2002, through the overall restructuring of Kangtai Co., Ltd. into a joint-stock company. On October 24, 2002, Kangtai Co., Ltd. passed a shareholders' resolution to convert the company into a joint-stock company based on the audited net assets of 175 million yuan as of September 30, 2002. On December 11, 2002, the company obtained the "Business License" issued by the Shenzhen Administration for Industry and Commerce.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hangzhou Hekun Enterprise Management Co., Ltd. | General Legal Person | 1600.00 | 1.78 |
| 2 | E Fund ChiNext Board ETF | Fund | 1320.16 | 1.47 |
| 3 | CSI 500 ETF | Fund | 974.13 | 1.08 |
| 4 | China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A | Fund | 882.99 | 0.98 |
| 5 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 798.66 | 0.89 |
| 6 | Yinhua CSI Innovative Pharmaceutical Industry ETF | Fund | 641.63 | 0.71 |
| 7 | Harvest CSI Vaccine and Biotechnology ETF | Fund | 56.40 | 0.06 |
| 8 | China Merchants CSI Vaccine and Biotechnology ETF | Fund | 4.98 | 0.01 |
5. Concept Sectors
- Convertible Bonds
- Biological Vaccine
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- Low-Profit Stock
- Planned Share Reduction
- ChiNext Index
- Small Cap Growth
- Technology 100
- SZSE Growth Index
- ChiNext 300
- ChiNext Blue Chip
- ChiNext Technology
- ChiNext Pharmaceutical
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information